Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Faculty Members have conducted research related to the Relationship Between Single-Nucleotide Polymorphisms of Tumor Necrosis Factor Alpha, Interleukin-10, Factor Ii and Factor V With Risk of Inhibitor Development in Patients With Severe Hemophilia A
Gholamreza Toogeh
Gholamreza Toogeh

Associate Professor of Hematology & Oncology

Department Internal Medicine

School of Medicine

Imam Khomeini Hospital Complex

Thrombosis Hemostasis Research Center

Tehran University of Medical Sciences

All Documents
1. A Randomized, Two-Armed, Double-Blind, Single-Dose, Cross-Over, Bioequivalence Clinical Trial to Compare Pharmacokinetic Parameters and Safety of Recombinant Human Factor Viii With Fc Fusion Produced by Aryogen Pharmed Company Versus Elocta® (Reference Product) in Previously Treated Patients With Severe Haemophilia A, Annals of Hematology (2025)
2. A Randomized, Two-Armed, Double-Blind, Single-Dose, Cross-Over, Bioequivalence Clinical Trial to Compare Pharmacokinetic Parameters and Safety of Recombinant Human Factor Viii With Fc Fusion Produced by Aryogen Pharmed Company Versus Elocta® (Reference Product) in Previously Treated Patients With Severe Haemophilia A, Annals of Hematology (2025)
3. Efficacy and Safety of Aspiration and Intra-Articular Injection of Tranexamic Acid in Acute Knee Hemarthrosis of Adult Haemophilic Patients: A Randomized Clinical Trial Study, Haemophilia (2025)
4. Rad51 and Rad50 Genetic Polymorphisms From Homologous Recombination Repair Pathway Are Associated With Disease Outcomes and Organ Toxicities in Aml, Blood Research (2024)
5. Von Willebrand Factor Neutralizing and Non-Neutralizing Alloantibodies in 213 Subjects With Type 3 Von Willebrand Disease Enrolled in 3Winters-Ips, Journal of Thrombosis and Haemostasis (2023)
6. Association Between Perceived Stress and Neutropenia in Patients With Leukemia Under Chemotherapy, International Journal of Hematology-Oncology and Stem Cell Research (2022)
7. Reversible Acute Lung Injury Due to Bleomycin, Tanaffos (2022)
8. Von Willebrand Factor Propeptide and Pathophysiological Mechanisms in European and Iranian Patients With Type 3 Von Willebrand Disease Enrolled in the 3Winters-Ips Study, Journal of Thrombosis and Haemostasis (2022)
9. Comparison of Long-Acting G-Csf (Pd-Lasta) With Short-Acting G-Csf (Pd-Grastim) in Neutrophil Recovery Following Consolidation Chemotherapy With High-Dose Cytarabine in Acute Myeloid Leukemia: A Randomized Clinical Trial, International Journal of Hematology-Oncology and Stem Cell Research (2021)
10. Genetic Analysis of Non-Severe Hemophilia a Phenotype With a Discrepancy Between One-Stage and Chromogenic Factor Viii Activity Assays, Transfusion and Apheresis Science (2021)
11. Genotypes of European and Iranian Patients With Type 3 Von Willebrand Disease Enrolled in 3Winters-Ips, Blood Advances (2021)
12. Genotypes of European and Iranian Patients With Type 3 Von Willebrand Disease Enrolled in 3Winters-Ips, Blood Advances (2021)
13. The Effects of Curcumin on the Side Effects of Anticancer Drugs in Chemotherapy: A Randomized Controlled Trial, Advances in Experimental Medicine and Biology (2021)
14. Thrombophilia, Anticoagulant Therapy, and Pregnancy Outcome in Women With Poor Obstetric History, Iranian Journal of Blood and Cancer (2021)
15. Bleeding Symptoms in Patients Diagnosed As Type 3 Von Willebrand Disease: Results From 3Winters-Ips, an International and Collaborative Cross-Sectional Study, Journal of Thrombosis and Haemostasis (2020)
16. Bleeding Symptoms in Patients Diagnosed As Type 3 Von Willebrand Disease: Results From 3Winters-Ips, an International and Collaborative Cross-Sectional Study, Journal of Thrombosis and Haemostasis (2020)
17. Discrepancy Between the Results of One-Stage and Chromogenic Factor Viii:C Assays in Patients With Mild/Moderate Hemophilia A, Blood Coagulation and Fibrinolysis (2020)
18. Acute Compartment Syndrome After Knee Synovectomy in a Patient With Hemophilia A, JBJS Case Connector (2019)
19. A Double-Blind, Randomized Comparison Study Between Zytux™ Vs Mabthera® in Treatment of Cll With Fcr Regimen: Non-Inferiority Clinical Trial, International Journal of Hematology-Oncology and Stem Cell Research (2018)
20. Bone Structure-Related Biomarkers in Hemophilic Patients, Compared to Healthy Condition, Acta Medica Iranica (2018)
21. Pharmacokinetics, Clot Strength and Safety of a New Fibrinogen Concentrate: Randomized Comparison With Active Control in Congenital Fibrinogen Deficiency, Journal of Thrombosis and Haemostasis (2018)
22. Fertility Preservation in Iranian Cancer Patients: A Continuing Neglect, International Journal of Fertility and Sterility (2017)
23. In Silico Designing of a New Cysteine Analogue of Hirudin Variant 3 for Site Specific Pegylation, Research in Pharmaceutical Sciences (2017)
24. A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor, Clinical and Applied Thrombosis/Hemostasis (2016)
25. A Comparison of Efficacy Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Hereditary Fviii Deficiency With Inhibitor, Clinical and Applied Thrombosis/Hemostasis (2016)
26. Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor Vii (Aryoseven™) and Activated Prothrombin Complex Concentrates (Feiba™) to Treat Hemophilia a Patients With Inhibitors in Iran, Iranian Journal of Pharmaceutical Research (2016)
27. Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor Vii (Aryoseven™) and Activated Prothrombin Complex Concentrates (Feiba™) to Treat Hemophilia a Patients With Inhibitors in Iran, Iranian Journal of Pharmaceutical Research (2016)
28. Evaluation of Aryoseven Safety (Recombinant Activated Factor Vii) in Patients With Bleeding Disorders (An Observational Post-Marketing Surveillance Study), Iranian Journal of Pathology (2016)
29. Functional Outcome of Total Knee Arthroplasty in Patients With Haemophilia, Haemophilia (2016)
30. Identification of the First Iranian Family With “Γarg275cys” Mutation (Fibrinogen Tokyo Ii), Journal of Cellular and Molecular Anesthesia (2016)
31. Jak2v617f Allele Burden Measurement in Peripheral Blood of Iranian Patients With Myeloproliferative Neoplasms and Effect of Hydroxyurea on Jak2v617f Allele Burden, International Journal of Hematology-Oncology and Stem Cell Research (2016)
32. Prevalence and Prognostic Impact of Wilms' Tumor 1 (Wt1) Gene, Including Snp Rs16754 in Cytogenetically Normal Acute Myeloblastic Leukemia (Cn-Aml): An Iranian Experience, Clinical Lymphoma# Myeloma and Leukemia (2016)
33. Simultaneous Bilateral Total Knee Arthroplasty in Patients With Haemophilia: A Safe and Cost-Effective Procedure?, Haemophilia (2016)
34. Total Joint Replacement in Haemophilia a Patients With High Titre of Inhibitor Using a New Brand Recombinant Factor Viia (Aryoseven®), Haemophilia (2016)
35. A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency, Clinical and Applied Thrombosis/Hemostasis (2015)
36. A Comparison Between Recombinant Activated Factor Vii (Aryoseven) and Novoseven in Patients With Congenital Factor Vii Deficiency, Clinical and Applied Thrombosis/Hemostasis (2015)
37. Expression Analysis of Microrna-125 in Patients With Polycythemia Vera and Essential Thrombocythemia and Correlation With Jak2 Allele Burden and Laboratory Findings, International Journal of Laboratory Hematology (2015)
38. Expression Pattern of Key Micrornas in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase, International Journal of Laboratory Hematology (2015)
39. Polymorphism in the Dna Repair Gene Xrcc3 and Therapeutic Outcomes in Patients With Aml, Genetics in the Third Millennium (2015)
40. Concomitant Presence of Jak2 V617f Mutation and Bcr-Abl Translocation in a Pregnant Woman With Polycythemia Vera, Medical Oncology (2011)
41. Arms-Pcr Versus As-Pcr to Evaluate Jak2v617f Mutation in Patients With Non-Cml Myeloproliferative Neoplasms, Tehran University Medical Journal (2010)
42. Comparisions of Arms-Pcr and As-Pcr for the Evaluation of Jak2v617f Mutation in Patients With Non-Cml Myeloproliferative Neoplasms, International Journal of Hematology-Oncology and Stem Cell Research (2010)
43. Evaluation of Jak2 V617f Mutation and Correlations of This Mutation With Clinical and Laboratory Findings in Patients With Myeloproliferative Neoplasms, Journal of Isfahan Medical School (2010)